Anavex Life Sciences - AVXL Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price objectives for Anavex Life Sciences' stock. Their AVXL share price forecasts range from $11.00 to $80.00. On average, they anticipate the company's stock price to reach $41.80 in the next twelve months. This suggests a possible upside of 391.2% from the stock's current price.
View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts.

Anavex Life Sciences' stock was trading at $9.26 at the beginning of the year. Since then, AVXL stock has decreased by 8.1% and is now trading at $8.51.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AVXL earnings forecast.

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced its quarterly earnings data on Tuesday, February, 7th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03.

ETFs with the largest weight of Anavex Life Sciences (NASDAQ:AVXL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Anavex Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.80%), Silverarc Capital Management LLC (0.00%), Millennium Management LLC (1.07%), Susquehanna International Group LLP (0.00%), Charles Schwab Investment Management Inc. (0.72%) and Morgan Stanley (0.49%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends.

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVXL stock can currently be purchased for approximately $8.51.

Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $664.04 million. The biotechnology company earns $-47,980,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com.